Abbott Joins Race To Develop Nerve Growth Factor Antibody With PanGenetics Deal

Abbott will pay PanGenetics $170 million upfront for the Phase I antibody. Pfizer, Johnson & Johnson and Sanofi-Aventis are among the firms with NGF antibodies in development.